AZN Jan 2026 57.500 call
| Previous close | 12.80 |
| Open | 23.52 |
| Bid | 23.45 |
| Ask | 23.95 |
| Strike | 57.50 |
| Expiry date | 2026-01-16 |
| Day's range | 23.50 - 23.52 |
| Contract range | N/A |
| Volume | |
| Open interest | 48 |
Business WireNew data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
WILMINGTON, Del., May 19, 2024--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placeb
- Reuters
PRESS DIGEST-British Business - May 14
The following are the top stories on the business pages of British newspapers. - Anglo American rejected a raised takeover offer of 34 billion pounds ($42.67 billion) from BHP Group on Monday, saying the world's largest listed miner "continues to significantly undervalue" the company. - JPMorgan Chase has pledged a further 40 million pounds ($50.22 million) in philanthropic investments in the UK over five years in a sign of its increasing focus on Britain.
The TelegraphUK pharma giants pledge £430m investment in France after Macron charm offensive
Britain’s two biggest pharmaceutical companies have pledged £430m of investment in France after a charm offensive by Emmanuel Macron.
